Efficacy and safety of Xuezhikang and Ezetimibe combination therapy in the patients with dyslipidemia

doi:10.3969/j.issn.1672-5301.2018.01.016

Abstract：Objective To determine the priority on efficacy and safety of Xuezhikang and Ezetimibe combination therapy when compared with Xuezhikang single drug therapy in the patients with dyslipidemia.Methods In this randomized,single-center trial,thirty-two patients were enrolled and randomized into two groups,one group was Xuezhikang 1.2 g treatment(n=16),the other group was Xuezhikang 1.2 g and Ezetimibe 10 mg combination treatment (n=16).They were followed-up after 3-month treatment.Blood samples were collected and biochemical parameters were measured including lipid profiles,hepatic and renal function,fasting glucose,creatinine and hs-CRP both in the baseline and in follow-up period.The change of lipid profile after 3-month treatment were compared between the two groups.The change of hepatic and renal function,fasting glucose,creatinine and hs-CRP after 3-month treatment were also compared between the two groups.Results In Xuezhikang group,the lipid profile after 3-month treatment was as following,TG(1.14±0.67)mmol/L,TC (3.87±0.66)mmol/L,HDL-C (1.36±0.47)mmol/L,LDL-C (2.20±0.59)mmol/L,and in Xuezhikang combined Ezetimibe group,the lipid profile after 3-month treatment was as following,TG (1.51 ± 1.33)mmol/L,TC (3.99± 1.14)mmol/L,HDL-C (1.31 ± 0.48)mmol/L,LDL-C (2.08±0.75)mmol/L.The average lowering percentage of TC was 18％,and the average lowering percentage of LDL-C was 24.7％ in the Xuezhikang group.However,the average lowering percentage of TC was 24％,and the average lowering percentage of LDL-C was 37.7％ in Xuezhikang comibined Ezetimibe group.Hepatic and renal function,fasting glucose,creatinine was no significant change in both the groups during the follow-up period.Hs-CRP was decreased in both the groups after 3-month treatment and Xuezhikang and Ezetimibe combination therapy has the advantage of reduction of hs-CRP to a greater extent.Conclusion The strategy of Xuezhikang and Ezetimibe combination therapy was superior to Xuezhikang alone treatment in the aspect of lipid-lowering therapy,including efficacy of lipid lowering and safety.